echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Within 5 days, the pharmaceutical company received research from 90 institutions!

    Within 5 days, the pharmaceutical company received research from 90 institutions!

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    According to data from June 8 to June 12, about 103 listed companies in Shanghai and Shenzhen were investigated by institutions in the last five trading days, according to data from Pharmaceutical Network Corporate NewsA total of 15 companies were surveyed by more than 20 institutions in the list of institutional researchAmong them, Dongcheng Pharmaceuticals was investigated by up to 90 institutions, Kanghong Pharmaceuticals ranked second, 62 institutions to participate in the survey.
    On June 8, Dongcheng Pharmaceuticals was investigated by the institutions including China Europe Fund, Cathay Fund, SeaArrow billion investment, etc., the research content includes the company's operations and development, pet-ct configuration progress, nuclide raw materials supply of the recent situation, the consistency evaluation of calcium querataryceon.
    Dongcheng Pharmaceuticals said the company's recent business conditions are good, the operation of normal and orderlyThe first quarter 2020 report disclosed by Dongcheng Pharmaceuticals in April showed that operating income was RMB714 million, up 33.61% YoY; net profit attributable to shareholders of listed companies was RMB738.694 million, up 14.49% YoY; net profit attributable to shareholders of listed companies, net income attributable to shareholders of listed companies, net of non-recurring profit and loss, was RMB7183.59 million, up 4.53% YoY; and basic earnings per share of RMB0.0921.
    In terms of pet-ct configuration, the provinces that have basically completed the distribution include Anhui, Fujian, Henan and Guangdong;
    Company nuclide drug raw materials main source accelerator production and reactor production, accelerator production mainly rely on the company's nuclear drug centers, through accelerators to accelerate the corresponding raw materials, you can obtain a specific nuclide, the way is simple and flexible; This year, the arrival time and customs clearance efficiency of imported nuclide raw material flights in February-March have been longer than in the past, but the supply of raw materials has not been affected and has now returned to normal levels in previous yearsCompany nuclide raw material supply, continuous stability, quality in line with the requirements.
    It is understood that the domestic nuclear drug market in 2017 reached 4.4 billion yuan, the market size is expected to reach 10.6 billion yuan in 2022China's nuclear medicine per capita expenditure is less than 1/10 of the United States, the future of the space for improvement is hugeAs the main competitor of the domestic nuclear drug market, Dongcheng Pharmaceutical co-spokes account for more than 70% of the market, showing a bipolar competition pattern, with a significant competitive advantage.
    On the issue of consistency evaluation of calcium quhonoconosultry, Dongcheng Pharmaceuticals said that the product is a modified type product, the "injection consistency evaluation guidance" issued by the country some time ago did not mention how to improve the consistency evaluation of the product, but it is understood that because there are too many modified dosage type products, the relevant departments are studying the guidance on the consistency evaluation of modified version productsAt the same time, in order to broaden the product sales channels, enhance market share, the company is currently in accordance with the new registration regulations and requirements of the report and the original research consistent with the registration of the water needle dosage form, after approval will be regarded as through the consistency evaluation.
    In addition, in response to the pharmaceutical companies to enter the field of nuclear drugs, the company mentioned that nuclear medicine belongs to the sub-sector, high-tech barriers industry, but in precision medicine and diagnosis and treatment integration has a unique advantage in the industry, especially in tumor diagnosis, treatmentAt present, the company has invested in and in the construction of nuclear medicine center will be more than 30, in the domestic nuclear medicine network layout has a certain advantage, with more enterprises to join nuclear medicine, cooperation with Dongcheng, will further promote the development and growth of Dongcheng nuclear medicine.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.